Skip to main navigation Skip to search Skip to main content

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)

  • S. Horgan
  • , J. Crowley
  • , J. Feely
  • , B. McAdam
  • , E. Shanahan
  • , C. Vaughan
  • The Adelaide Hospital
  • Galway University Hospital
  • St James's Hospital
  • Beaumont Hospital
  • Trinity College Dublin
  • Mercy University Hospital

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

7 Citations (Scopus)

Abstract

Background: Statins are proven to reduce cardiovascular risk; however, substantial risk remains in patients on statin therapy. Persisting dyslipidaemia is likely to play a contributory role. Aim: To assess the prevalence of persisting lipid abnormalities in patients treated with statins. Methods: DYSIS was a cross-sectional study of 22,063 patients in Europe and Canada. 900 Irish patients participated. All patients were ≥45 years and treated with statins for ≥3 months. Data were collected from the patients' records. ESC guidelines were used to classify risk and to define lipid levels. Results: Mean age was 66.1 years with women representing 40.7%. 78.6% were high-risk patients; that is 53.9% with cardiovascular disease (CVD), 20.1% with diabetes and 15.9% with a SCORE risk ≥5%. Total cholesterol was not at goal in 34.4% of all patients. LDL-C was elevated in 30.8% of all patients and in 30% at high risk. Low HDL-C was found in 34.7% of high-risk patients compared to 16.9% of patients with an ESC score <5%. In diabetics without CVD, low HDL-C and elevated TGs were found in 46 and 44.3%, respectively. Conclusions: Despite statin therapy, a significant number of patients have persistent dyslipidaemia. While LDL-C targets are suboptimal in three out of ten patients, the prevalence of low HDL-C and high TGs in high-risk patients is greater than one in three. A more integrated approach to the treatment of patients with dyslipidaemia is warranted. Clinical trials are needed to assess the impact of therapies that raise HDL-C and lower elevated TGs.

Original languageEnglish
Pages (from-to)343-349
Number of pages7
JournalIrish Journal of Medical Science
Volume180
Issue number2
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cardiovascular risk
  • Cross-sectional study
  • DYSIS
  • Dyslipidaemia
  • HDL-C
  • LDL-C
  • Lipids
  • Statin
  • Triglycerides

Fingerprint

Dive into the research topics of 'Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)'. Together they form a unique fingerprint.

Cite this